About Sriam Labs Private Limited
Data last updated: 03 September 2025
Sriam Labs Private Limited is a private limited company based in Yadadri Bhuvanagiri District, Telangana, India, a subsidiary of Laurus Labs Limited. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 12 February 2002, the company has been in operation for over 24 years.
Registered with ROC Hyderabad under CIN U24239TG2002PTC038490.
Capital: an authorised share capital of ₹14.5 Cr and a paid-up capital of ₹14.2 Cr. Formerly known as Sai Ram Organics Private Limited. It is led by directors including Venkateswar Reddy Gogireddy and Uma Maheswar Rao Vasireddi.
Last AGM: 12 June 2025. Financial statements filed for year ended 31 March 2025. Office: Sy. No. 505 Padamati Somaram Road Bibinagar (Village & Mandal), Yadadri Bhuvanagiri District, Telangana, India – 508126.
As per the financials filed for FY 2025, the company reported a revenue of ₹62.63 Cr, a decline of 14% compared to the previous year.
The company has a workforce of approximately 97 employees as per the latest available data. It operates as a subsidiary of Laurus Labs Limited.
The company is associated with 1 brand - Laurus Labs. As per MCA filings, the company has satisfied charges of ₹84.73 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website sriam-labs.lookchem.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered AddressSy. No. 505 Padamati Somaram Road Bibinagar (Village & Mandal), Yadadri Bhuvanagiri District, Telangana, India – 508126
-
IndustryPharma, API Manufacturers
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Sriam Labs Private Limited
Sriam Labs Private Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is U24239AP2002PTC121365, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24239AP2002PTC121365 | Current |
| U24239TG2002PTC038490 | Previous |
| U24239AP2002PTC038490 | Previous |
Associated Brands with Sriam Labs Private Limited
Sriam Labs Private Limited operates one associated brand: Laurus Labs. These brands represent Sriam Labs Private Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical and biotechnology company | lauruslabs.com |
Competitors & Alternatives of Sriam Labs Private Limited
Brands and companies operating in the same space as Sriam Labs Private Limited include Symbiotec, Sterling Pharma Solutions, Provepharm Life Solutions and 4 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Symbiotec
|
Non-sterile steroid hormone-based APIs and intermediates are manufactured. | Indore, India, India | 2002 |
Sterling Pharma Solutions
|
Contract development, manufacturing, and analytical services for APIs are offered. | Dudley, United Kingdom, United Kingdom | 2016 |
Provepharm Life Solutions
|
APIs and drug products are developed and valorized in pharmaceuticals. | Marseille, France, France | 1998 |
Apicore
|
APIs are manufactured and custom synthesis services are provided. | Somerset, United States, United States | 2004 |
SeQuent
|
APIs are developed and manufactured for therapeutic areas. | Bengaluru, India, India | 2002 |
Jubilant Pharma
|
Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company. | Noida, India, India | 1978 |
Bellen Chemistry
|
APIs and intermediates are researched and manufactured, specializing in heterocycles. | Beijing, China, China | 2007 |
Business Activity of Sriam Labs Private Limited
Sriam Labs Private Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Sriam Labs Private Limited
Sriam Labs Private Limited is audited by Deloitte Haskins & Sells for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Deloitte Haskins & Sells | blur-value | blur-value | blur-value |
Board of Directors of Sriam Labs Private Limited
Sriam Labs Private Limited is currently managed by 6 directors, with 9 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Venkateswar Reddy Gogireddy
Also directs:
Laurus Labs Limited
|
Company Secretary | 01 Apr 2020 | 6 Years 3 Months | Current |
|
Uma Maheswar Rao Vasireddi
Also directs:
Laurus Bio Private Limited
|
Director | 23 Jul 2020 | 5 Years 11 Months | Current |
|
Venkata Lakshmana Rao Chunduru
Also directs:
Laurus Labs Limited
|
Director | 25 Jul 2014 | 11 Years 11 Months | Current |
|
Krishna Chaitanya Chava
Also directs:
Laurus Labs Limited, Laurus Synthesis Private Limited, Laurus Specialty Chemicals Private Limited and 1 more
|
Director | 25 Jul 2019 | 6 Years 11 Months | Current |
| Srinivasa Rao Suryadevara | Director | 25 Jul 2014 | 11 Years 11 Months | Current |
Financials of Sriam Labs Private Limited FY 2025 filings available
Sriam Labs Private Limited reported revenue of ₹62.63 Cr (down 14% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Sriam Labs Private Limited
As of FY 2023, Sriam Labs Private Limited's shareholding pattern shows 100.00% by promoters. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings of Sriam Labs Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Dec 2020 | Axis Bank Limited | ₹10 Cr | Satisfied |
| 30 Apr 2015 | Andhra Bank | ₹6 Cr | Satisfied |
| 21 Jan 2015 | Andhra Bank | ₹6.7 Lakh | Satisfied |
| 18 Jun 2014 | Andhra Bank | ₹6 Cr | Satisfied |
| 28 Jan 2013 | Andhra Bank | ₹5.6 Cr | Satisfied |
Total charge records: 12 View all charges
Employees and EPFO Compliance at Sriam Labs Private Limited
Sriam Labs Private Limited has a workforce of 97 employees as of Apr 09, 2024.
Employee Count & EPFO Data of Sriam Labs Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Sriam Labs Private Limited
GSTIN & GST Filing Data of Sriam Labs Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Sriam Labs Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Sriam Labs Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Sriam Labs Private Limited
MSME Payment Delays by Sriam Labs Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Sriam Labs Private Limited
Subsidiaries & Group Companies of Sriam Labs Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Sriam Labs Private Limited with ownership details.
MCA Filings & Documents of Sriam Labs Private Limited
MCA Filings & Documents of Sriam Labs Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Sriam Labs Private Limited
Recent News on Sriam Labs Private Limited
Frequently Asked Questions about Sriam Labs Private Limited
Sriam Labs Private Limited is an active private limited company in the pharma sector based in Yadadri Bhuvanagiri District, Telangana, India. It was incorporated on 12 February 2002 (24+ years old) and is registered under CIN U24239AP2002PTC121365. The company has 97 employees.
Sriam Labs Private Limited reported revenue of ₹62.63 Cr for FY 2025 (down 14.00% YoY).
The current directors of Sriam Labs Private Limited are:
The primary industry of Sriam Labs Private Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.
Sriam Labs Private Limited can be reached at the registered office: Sy. No. 505 Padamati Somaram Road Bibinagar Village & Mandal, Yadadri Bhuvanagiri District, Telangana, India – 508126, or through the website sriam-labs.lookchem.com.
The authorised capital is ₹14.5 Cr, and the paid-up capital is ₹14.2 Cr.